INK does not purport to tell people, or suggest to people, what they should buy or sell for INK is not an investment advisory service, a financial planner, an investment advisor nor a Filings may at any time contain errors and by using this site youДЄcknowledge this fact. Parties legally required or permitted to do so. You acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other Data is provided вЂњas isвЂќ and by using this site Insider information is based on filings made on the SystemДЇor Electronic Disclosure for Insiders (SEDIВ®). All information and opinionД®xpressed herein is subject to change without notice. INK makes no guarantee of accuracy or completeness. INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion See business summaryДisclaimer :: Use of this site is subject to, and your continued useД¬onstitutes your express agreement to be bound by, our Legal and Terms of Use. The IVD segment designs, develops and manufactures component products and technologies for diagnostic immunoassay, as well as molecular tests and biomedical research applications, with products that include protein stabilization reagents, substrates, surface coatings and antigens. The Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices, as well as drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that includes coronary, peripheral, neurovascular and structural heart, among others. The Company operates through two segments: Medical Device and In Vitro Diagnostics (IVD).

is a provider of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. Industry: Medical Equipment, Supplies & Distribution

Stock srdx